Adrenaclick Patent Expiration

Adrenaclick is a drug owned by Impax Laboratories Llc. It is protected by 4 US drug patents filed from 2013 to 2020. Out of these, 3 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 12, 2027. Details of Adrenaclick's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7905352 Kits containing medicine injection devices and containers
Apr, 2027

(2 years from now)

Active
US10166334 Medicine injection apparatuses
Jan, 2025

(3 months from now)

Active
US10166344 Injection needle assembly
Jan, 2025

(3 months from now)

Active
US5665071 Reloadable automatic or manual emergency injection system
May, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adrenaclick's patents.

Given below is the list of recent legal activities going on the following patents of Adrenaclick.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 10 Aug, 2022 US7905352
Payment of Maintenance Fee, 4th Year, Large Entity 21 Jun, 2022 US10166344
Payment of Maintenance Fee, 4th Year, Large Entity 31 May, 2022 US10166334
7.5 yr surcharge - late pmt w/in 6 mo, Large Entity 30 Jan, 2019 US7905352
Payment of Maintenance Fee, 8th Year, Large Entity 30 Jan, 2019 US7905352
Patent Issue Date Used in PTA Calculation 01 Jan, 2019 US10166344
Recordation of Patent Grant Mailed 01 Jan, 2019 US10166344
Patent Issue Date Used in PTA Calculation 01 Jan, 2019 US10166334
Recordation of Patent Grant Mailed 01 Jan, 2019 US10166334
Issue Notification Mailed 12 Dec, 2018 US10166334

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Adrenaclick is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adrenaclick's family patents as well as insights into ongoing legal events on those patents.

Adrenaclick's Family Patents

Adrenaclick has patent protection in a total of 15 countries. It's US patent count contributes only to 34.0% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Adrenaclick.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Adrenaclick's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 12, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Adrenaclick Generics:

Epinephrine is the generic name for the brand Adrenaclick. 4 different companies have already filed for the generic of Adrenaclick, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adrenaclick's generic

Alternative Brands for Adrenaclick

There are several other brand drugs using the same active ingredient (Epinephrine) as Adrenaclick. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.


Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Adrenaclick's active ingredient. Check the complete list of approved generic manufacturers for Adrenaclick





About Adrenaclick

Adrenaclick is a drug owned by Impax Laboratories Llc. Adrenaclick uses Epinephrine as an active ingredient. Adrenaclick was launched by Impax in 2009.

Approval Date:

Adrenaclick was approved by FDA for market use on 25 November, 2009.

Active Ingredient:

Adrenaclick uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient

Dosage:

Adrenaclick is available in injectable form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.3MG/DELIVERY INJECTABLE Prescription INTRAMUSCULAR, SUBCUTANEOUS
EQ 0.15MG/DELIVERY INJECTABLE Prescription INTRAMUSCULAR, SUBCUTANEOUS